close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NeoGenomics, Inc. - Common Stock (NQ:NEO)

18.62 -0.27 (-1.40%)
Streaming Delayed Price Updated: 11:00 AM EDT, Sep 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NeoGenomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
News headline image
3 Healthcare Stocks We’re Skeptical Of
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva... 
Via StockStory
News headline image
3 Reasons NEO is Risky and 1 Stock to Buy Instead
What a time it’s been for NeoGenomics. In the past six months alone, the company’s stock price has increased by a massive 138%, reaching $19.30 per share. Th... 
Via StockStory
Topics Bankruptcy Supply Chain
News headline image
NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference ↗
NeoGenomics (NASDAQ:NEO) executives outlined the company’s strategy to expand its role in community-based precision oncology, emphasizing growth in next-generation sequencing, minimal residual disease... 
Via MarketBeat
News headline image
1 Unpopular Stock That Deserves a Second Chance and 2 We Turn Down
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t... 
Via StockStory
Topics Economy
NeoGenomics (NASDAQ:NEO): Quality Stock After Q2 Earnings Beat and Raised Guidance ↗
Via Chartmill
Topics Earnings
News headline image
A Look Back at Testing & Diagnostics Services Stocks’ Q2 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at NeoGenomics (NASDAQ:NEO) and ... 
Via StockStory
News headline image
NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring
From NeoGenomics, Inc.
Via Business Wire
News headline image
3 Unprofitable Stocks Walking a Fine Line
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th... 
Via StockStory
News headline image
3 Stocks Under $50 with Open Questions
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However... 
Via StockStory
News headline image
3 Healthcare Stocks with Questionable Fundamentals
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not on... 
Via StockStory
News headline image
Why NeoGenomics (NEO) Stock Is Up Today
What Happened? Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 15.8% in the afternoon session after the company reported seco... 
Via StockStory
News headline image
3 of Wall Street’s Favorite Stocks with Questionable Fundamentals
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember... 
Via StockStory
News headline image
NeoGenomics Q2 Earnings Call Highlights ↗
NeoGenomics (NASDAQ:NEO) raised its full-year 2026 revenue and adjusted EBITDA guidance after reporting second-quarter revenue growth that exceeded its prior outlook, led by higher-value clinical... 
Via MarketBeat
Topics Earnings
News headline image
NeoGenomics’s (NASDAQ:NEO) Q2 CY2026: Beats On Revenue
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 11.2% year on... 
Via StockStory
News headline image
NeoGenomics Reports Second Quarter 2026 Results
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics (NEO) Q2 Earnings Report Preview: What To Look For
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be announcing earnings results this Tuesday afternoon. Here’s what you need to know. NeoG... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Momentum Stock with Solid Fundamentals and 2 We Avoid
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, pos... 
Via StockStory
News headline image
NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS
From NeoGenomics, Inc.
Via Business Wire
News headline image
3 Small-Cap Stocks with Questionable Fundamentals
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and... 
Via StockStory
News headline image
NeoGenomics (NEO) Stock Trades Up, Here Is Why
What Happened? Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 3.4% in the afternoon session after the company announced the ... 
Via StockStory
Topics Intellectual Property Lawsuit
News headline image
NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026
From NeoGenomics, Inc.
Via Business Wire
News headline image
A Look Back at Testing & Diagnostics Services Stocks’ Q1 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack
Looking back on testing & diagnostics services stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including NeoGenomics (NASDAQ:NEO) a... 
Via StockStory
News headline image
NeoGenomics Appoints Carolyn Starrett to its Board of Directors
From NeoGenomics, Inc.
Via Business Wire
News headline image
1 Unprofitable Stock for Long-Term Investors and 2 Facing Headwinds
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. Unprofi... 
Via StockStory
News headline image
NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics to Present New Research at ASCO Annual Meeting 2026
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics to Participate in Upcoming Investor Conferences
From NeoGenomics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.